Replies to post #342346 on Anavex Life Sciences Corp (AVXL)

[abew4me]

Well, you have to remember that that Press Release (in June of 2021) was a follow up from their original Press Release in November of 2020. (See below)

"Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference"
November 06, 2020 10:45 ET | Source: Anavex Life Sciences Corp.

https://www.globenewswire.com/news-release/2020/11/06/2122112/0/en/Proof-of-Concept-Controlled-Phase-2-Clinical-Trial-Data-Evaluating-ANAVEX-2-73-blarcamesine-in-Parkinson-s-Disease-Dementia-Presented-at-CTAD-2020-Conference.html

And frankly, we're still waiting for the rest of the genomic data from that PDD trial...which should be released sometime this year. (Fingers crossed)

The bottom line is that the market doesn't like partial data from our trials vs. partial data from other biotech companies that are backed by WS.

In hindsight, this is a good lesson for us shareholders to be patient while TGD gathers all of the data from the AVATAR trial so that it can be presented in its entirety.

AVATAR will be our first P3 trial to prove the MOA of our small molecule drug, A2-73.

Should be a real eye-opener!